XML 72 R55.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 26, 2023 | Nov. 09, 2023 | Jun. 12, 2023 | May 12, 2017 | Oct. 31, 2021 | Aug. 31, 2021 | Dec. 31, 2016 | Dec. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2023 | Oct. 03, 2023
Sanofi [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500 |
Milestone payment receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500
Development and launch milestone payment receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000
Johnson And Johnson [Member] | Settlement And License Agreement Alvotech And Teva [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum entry date for granting license entry |  |  | Feb. 21, 2025 |  |  |  |  |  |  |  |  |  |  |  |
Biolojic Design Ltd [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional development and milestone payments receivable |  |  |  |  |  |  |  | $ 500 |  |  |  |  |  | 500 |
Biolojic Design Ltd [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment | $ 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement milestone payments |  | $ 100 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement milestone amount increase |  | $ 125 |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Pharma [Member] | Research and Development Expense [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of research and development expenses incurred |  |  |  |  |  |  |  | $ 35 |  |  |  |  |  |  |
Otsuka [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  | $ 50 |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 35 | $ 15 |  |
Takeda [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 30 |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  | 20 |  |  | $ 25 |  |  |  |  |
Collaborative agreement milestone payments |  |  |  |  |  |  | $ 519 |  |  |  |  |  |  |  |
Alvotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 400 |
MedinCell [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  | $ 3 |  |  |  |  |  |
Collaborative agreement milestone payments |  |  |  |  |  | $ 105 |  |  |  |  |  |  |  |  |
MODAG [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement potential aggregate milestone payments amount |  |  |  |  | $ 30 |  |  |  |  |  |  |  |  |  |
MODAG [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncash or Part Noncash Acquisitions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  | $ 10 |  |  |  |

X
- Definition Additional development and milestone payments receivable. + References No definition available. + Details
Name: | teva_AdditionalDevelopmentAndMilestonePaymentsReceivable
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative agreement milestone amount increase. + References No definition available. + Details
Name: | teva_CollaborativeAgreementMilestoneAmountIncrease
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement Milestone Payments + References No definition available. + Details
Name: | teva_CollaborativeAgreementMilestonePayments
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development and launch milestone payment receivable. + References No definition available. + Details
Name: | teva_DevelopmentAndLaunchMilestonePaymentReceivable
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License agreement potential aggregate milestone payments amount. + References No definition available. + Details
Name: | teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum entry date for granting license entry. + References No definition available. + Details
Name: | teva_MaximumEntryDateForGrantingLicenseEntry
Namespace Prefix: | teva_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | teva_MilestonePayment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment receivable. + References No definition available. + Details
Name: | teva_MilestonePaymentReceivable
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payments + References No definition available. + Details
Name: | teva_UpfrontPayments
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_NoncashOrPartNoncashAcquisitionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=teva_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_JohnsonAndJohnsonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_AgreementAxis=teva_SettlementAndLicenseAgreementAlvotechAndTevaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_BiolojicDesignLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_RoyaltyPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_TakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_MedincellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_ModagMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |